[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Barchart Premier: The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Dexcom Inc (DXCM)

Dexcom Inc (DXCM)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 28,230,470
  • Shares Outstanding, K 385,873
  • Annual Sales, $ 4,662 M
  • Annual Income, $ 836,300 K
  • EBIT $ 1,033 M
  • EBITDA $ 1,285 M
  • 60-Month Beta 1.45
  • Price/Sales 6.14
  • Price/Cash Flow 26.81
  • Price/Book 9.69

Options Overview Details

View History
  • Implied Volatility 40.86% (+0.71%)
  • Historical Volatility 44.26%
  • IV Percentile 33%
  • IV Rank 26.28%
  • IV High 77.57% on 10/30/25
  • IV Low 27.78% on 08/05/25
  • Expected Move (DTE 9) 3.51 (4.93%)
  • Put/Call Vol Ratio 0.26
  • Today's Volume 2,389
  • Volume Avg (30-Day) 3,145
  • Put/Call OI Ratio 1.00
  • Today's Open Interest 104,205
  • Open Int (30-Day) 99,312
  • Expected Range 67.72 to 74.74

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 27 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $0.60
  • Number of Estimates 9
  • High Estimate $0.64
  • Low Estimate $0.58
  • Prior Year $0.48
  • Growth Rate Est. (year over year) +25.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
61.54 +15.75%
on 05/18/26
78.91 -9.73%
on 06/10/26
+9.60 (+15.58%)
since 05/15/26
3-Month
56.72 +25.58%
on 04/29/26
78.91 -9.73%
on 06/10/26
+3.91 (+5.81%)
since 03/17/26
52-Week
54.11 +31.64%
on 11/07/25
89.98 -20.84%
on 07/30/25
-10.60 (-12.95%)
since 06/17/25

Most Recent Stories

More News
1 Cash-Producing Stock with Impressive Fundamentals and 2 We Find Risky

1 Cash-Producing Stock with Impressive Fundamentals and 2 We Find Risky

GIII : 34.05 (-2.32%)
INSE : 8.00 (-1.60%)
DXCM : 71.23 (-2.64%)
3 Reasons Investors Love DexCom (DXCM)

3 Reasons Investors Love DexCom (DXCM)

DXCM : 71.23 (-2.64%)
1 Surging Stock with Impressive Fundamentals and 2 That Underwhelm

1 Surging Stock with Impressive Fundamentals and 2 That Underwhelm

CROX : 124.53 (-2.01%)
VSH : 60.33 (-0.13%)
DXCM : 71.23 (-2.64%)
Dexcom CONNECT Study: The Most Significant Clinical Study Demonstrating CGM Benefits for People with Type 2 Diabetes Not Using Insulin

Dexcom sponsored CONNECT randomized controlled trial expected to help establish new standard of care for CGM use by people with Type 2 diabetes not using insulin around the world. ...

DXCM : 71.23 (-2.64%)
Is DexCom Stock Underperforming the Dow?

DexCom has lagged behind the Dow Jones over the past year, yet analysts remain highly bullish about the stock’s outlook.

GEHC : 61.15 (-3.29%)
$DOWI : 51,492.55 (-0.98%)
DXCM : 71.23 (-2.64%)
Dexcom Reaffirms CGM Benefits for All People With Diabetes and Continues Momentum Toward Earlier Stage Intervention and Preventative Care at ADA 2026

Highly anticipated presentation of results from the CONNECT randomized control trial will be presented during the ADA Scientific Sessions conference on Saturday, June 6 at 1:45 p.m. CDT. ...

DXCM : 71.23 (-2.64%)
Dexcom Releases Customer Advisory Council Report, Outlining Ongoing Commitments to Enhancing Product Performance and User Experience

Company establishes permanent council to drive ongoing innovation guided by community feedback Report outlines targeted commitments Dexcom is making to...

DXCM : 71.23 (-2.64%)
The DexCom Stock Turnaround Is Showing Real Signs of Life

DexCom (DXCM) shares have put together an encouraging short-term bounce as the company maps out a multi-year growth algorithm. The stock currently carries a 8% “Sell” rating, but that’s up from the...

DXCM : 71.23 (-2.64%)
Redefining CGM for People With Type 2 Diabetes: Dexcom Announces Dexcom Flex in Germany

Dexcom has announced a new continuous glucose monitoring system designed for people using basal insulin, oral therapies or GLP-1 receptor agonists 1 . The new system will be available...

DXCM : 71.23 (-2.64%)
DexCom Maps G8 Launch, Coverage Expansion and Double-Digit Growth at Investor Day

DexCom (NASDAQ:DXCM) used its 2026 Investor Day to outline a long-range plan centered on new product launches, broader insurance coverage for continuous glucose monitoring, international expansion and...

DXCM : 71.23 (-2.64%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Buy with a Weakening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

DexCom, Inc. is a medical device company focused on the design, development and commercialization of continuous glucose monitoring systems (CGM). These are for ambulatory use by people with diabetes and by healthcare providers for the treatment of diabetic and non-diabetic patients. A key element of...

See More

Key Turning Points

3rd Resistance Point 76.72
2nd Resistance Point 75.49
1st Resistance Point 73.36
Last Price 71.23
1st Support Level 70.00
2nd Support Level 68.77
3rd Support Level 66.64

See More

52-Week High 89.98
Fibonacci 61.8% 76.28
Fibonacci 50% 72.04
Last Price 71.23
Fibonacci 38.2% 67.81
52-Week Low 54.11

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.